Elevating Veterinary Healthcare: Innovations in Detection and Treatment of Drug Residues and Additives Through Biotechnological Advances
Introduction of Elevating Veterinary Healthcare
In the rapidly advancing domain of veterinary healthcare, the paramount concern is the safety and efficacy of animal treatments, which directly impact animal welfare and the quality of animal-derived products. Innovations in biotechnology, particularly the development of anti-small molecule antibodies and small molecule competitive antigens, have emerged as pivotal tools for the precise detection and therapeutic management of veterinary drug residues and additives. These advancements are critical in safeguarding animal health and ensuring the integrity of the food chain.
Comprehensive Overview of Veterinary Drug Residues and Additives
Veterinary drug residues and additives constitute a wide array of substances administered in animal healthcare and feed, potentially persisting in the animal products. These include, but are not limited to, antibiotics, hormones, and growth promoters, each posing unique challenges to animal health and human safety if not meticulously controlled.
Classifications and Significant Small Molecules
Antibiotics: Critical molecules such as tetracyclines, sulfonamides, and penicillins are indispensable in combating bacterial infections in livestock. The vigilant monitoring of their residues addresses the growing concerns around antimicrobial resistance and the safeguarding of food safety.
Hormones and Growth Promoters: Compounds like trenbolone and zeranol are utilized to improve growth efficiency in livestock. Stringent regulation of their residues is essential due to their potential endocrine-disrupting effects on consumers.
Antiparasitics: Key medications including ivermectin and praziquantel play a vital role in managing parasitic infestations. Ensuring these substances remain within safe levels in animal products is crucial for adhering to health standards and preventing adverse health outcomes.
Diagnostic and Therapeutic Innovations
Diagnostics: The advent of anti-small molecule antibodies has been transformative in the field of diagnostics, offering unprecedented specificity and sensitivity in detecting veterinary drug residues. This technological leap enables the thorough screening of animal products, such as tissue, milk, and eggs, aligning with regulatory compliance and enhancing consumer protection.
Therapeutics: The application of small molecule competitive antigens introduces a groundbreaking therapeutic avenue. By functioning as decoys or inhibitors, these antigens hold the potential to counteract the negative impacts of drug residue accumulation, fostering safer veterinary practices and contributing to the production of residue-free animal products.
Conclusion
he integration of cutting-edge biotechnological tools in veterinary diagnostics and therapeutics signifies a monumental stride forward in animal healthcare and food safety. The precision offered by anti-small molecule antibodies and small molecule competitive antigens is instrumental in navigating the complexities of drug residues and additives, fulfilling the rigorous safety standards of the contemporary global marketplace.
Embark on a journey to redefine veterinary medicine with our state-of-the-art biotechnological solutions, designed to master the challenges posed by veterinary drug residues and additives. Engage with our innovative technologies to elevate standards in animal health and food safety, championing the welfare of animals and the health of consumers worldwide.
Leveraging Genemedi's expertise, we have crafted antigens and antibodies tailored for the nuanced detection of various small molecules within veterinary drug residues and additives. Our suite of diagnostic tools, including ELISA, Lateral Flow Immunoassay (LFIA), Colloidal Gold Immunochromatographic Assay, Chemiluminescent Immunoassay (CLIA), Turbidimetric Inhibition Immunoassay (TINIA), Immunonephelometry, and Point-of-Care Testing (POCT), sets a new benchmark in precision and reliability, underscoring our commitment to advancing veterinary healthcare.
Product List
| Cat No. | Small molecules (Chemicals, Antibiotics, Mycotoxins, Hormones, Drugs of Abuse, etc.) | Carrier-coupled antigen/immunogen (hapten-carrier conjugates) |
Anti-Hapten Antibody | Bioactivity validation | ELISA IC50 (ppb) |
Order |
| GMP-SMT-1 | Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) | BSA-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings); OVA-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) | Anti-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) mouse monoclonal antibody; Anti-Sulfonamides Residue (SAs) (sulfamethoxazole (SMX), 5-atom-rings) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 |  |
| GMP-SMT-2 | Sulfonamides Residue (SAs) (6-atom-rings) | BSA-Sulfonamides Residue (SAs) (6-atom-rings); OVA-Sulfonamides Residue (SAs) (6-atom-rings) | Anti-Sulfonamides Residue (SAs) (6-atom-rings) mouse monoclonal antibody; Anti-Sulfonamides Residue (SAs) (6-atom-rings) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 | |
| GMP-SMT-3 | Sulfadiazine(SD) | BSA-Sulfadiazine(SD); OVA-Sulfadiazine(SD) | Anti-Sulfadiazine(SD) mouse monoclonal antibody; Anti-Sulfadiazine(SD) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 | |
| GMP-SMT-4 | Sulfaquinoxaline (SQX) | BSA-Sulfaquinoxaline (SQX); OVA-Sulfaquinoxaline (SQX) | Anti-Sulfaquinoxaline (SQX) mouse monoclonal antibody; Anti-Sulfaquinoxaline (SQX) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-5 | Sulfamethazine(SM2) | BSA-Sulfamethazine(SM2); OVA-Sulfamethazine(SM2) | Anti-Sulfamethazine(SM2) mouse monoclonal antibody; Anti-Sulfamethazine(SM2) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-5 | |
| GMP-SMT-6 | Sulfadimethoxine(SMD) | BSA-Sulfadimethoxine(SMD); OVA-Sulfadimethoxine(SMD) | Anti-Sulfadimethoxine(SMD) mouse monoclonal antibody; Anti-Sulfadimethoxine(SMD) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-7 | Sulfachloropyrazine | BSA-Sulfachloropyrazine; OVA-Sulfachloropyrazine | Anti-Sulfachloropyrazine mouse monoclonal antibody; Anti-Sulfachloropyrazine human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.20 | |
| GMP-SMT-8 | Florfenicol(FF) | BSA-Florfenicol(FF); OVA-Florfenicol(FF) | Anti-Florfenicol(FF) mouse monoclonal antibody; Anti-Florfenicol(FF) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-9 | Chloromycetin(CAP) | BSA-Chloromycetin(CAP); OVA-Chloromycetin(CAP) | Anti-Chloromycetin(CAP) mouse monoclonal antibody; Anti-Chloromycetin(CAP) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.3 | |
| GMP-SMT-10 | Chloramphenicol (TAP ) | BSA-Chloramphenicol (TAP ); OVA-Chloramphenicol (TAP ) | Anti-Chloramphenicol (TAP ) mouse monoclonal antibody; Anti-Chloramphenicol (TAP ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.3 | |
| GMP-SMT-11 | Chloramphenicols | BSA-Chloramphenicols; OVA-Chloramphenicols | Anti-Chloramphenicols mouse monoclonal antibody; Anti-Chloramphenicols human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.4 | |
| GMP-SMT-12 | Kanamycin(KAN) | BSA-Kanamycin(KAN); OVA-Kanamycin(KAN) | Anti-Kanamycin(KAN) mouse monoclonal antibody; Anti-Kanamycin(KAN) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-13 | Gentamicin(GM) | BSA-Gentamicin(GM); OVA-Gentamicin(GM) | Anti-Gentamicin(GM) mouse monoclonal antibody; Anti-Gentamicin(GM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-14 | Amikacin(AMK) | BSA-Amikacin(AMK); OVA-Amikacin(AMK) | Anti-Amikacin(AMK) mouse monoclonal antibody; Anti-Amikacin(AMK) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.1-0.2 | |
| GMP-SMT-15 | Streptomycin(STR) | BSA-Streptomycin(STR); OVA-Streptomycin(STR) | Anti-Streptomycin(STR) mouse monoclonal antibody; Anti-Streptomycin(STR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-16 | Apramycin(APM) | BSA-Apramycin(APM); OVA-Apramycin(APM) | Anti-Apramycin(APM) mouse monoclonal antibody; Anti-Apramycin(APM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.00 | |
| GMP-SMT-17 | Spectinomycin(SPM) | BSA-Spectinomycin(SPM); OVA-Spectinomycin(SPM) | Anti-Spectinomycin(SPM) mouse monoclonal antibody; Anti-Spectinomycin(SPM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.50 | |
| GMP-SMT-18 | Tobramycin | BSA-Tobramycin; OVA-Tobramycin | Anti-Tobramycin mouse monoclonal antibody; Anti-Tobramycin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-19 | Neomycin(NM) | BSA-Neomycin(NM); OVA-Neomycin(NM) | Anti-Neomycin(NM) mouse monoclonal antibody; Anti-Neomycin(NM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-21 | Lincomycin(LM) | BSA-Lincomycin(LM); OVA-Lincomycin(LM) | Anti-Lincomycin(LM) mouse monoclonal antibody; Anti-Lincomycin(LM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-22 | Pirlimycin(PIR) | BSA-Pirlimycin(PIR); OVA-Pirlimycin(PIR) | Anti-Pirlimycin(PIR) mouse monoclonal antibody; Anti-Pirlimycin(PIR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-23 | Erythromycin(EM) | BSA-Erythromycin(EM); OVA-Erythromycin(EM) | Anti-Erythromycin(EM) mouse monoclonal antibody; Anti-Erythromycin(EM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5-10 | |
| GMP-SMT-24 | Avermectin(AVM) | BSA-Avermectin(AVM); OVA-Avermectin(AVM) | Anti-Avermectin(AVM) mouse monoclonal antibody; Anti-Avermectin(AVM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2.00 | |
| GMP-SMT-25 | Doramectin(DOR) | BSA-Doramectin(DOR); OVA-Doramectin(DOR) | Anti-Doramectin(DOR) mouse monoclonal antibody; Anti-Doramectin(DOR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-26 | Tylosin(TYL) | BSA-Tylosin(TYL); OVA-Tylosin(TYL) | Anti-Tylosin(TYL) mouse monoclonal antibody; Anti-Tylosin(TYL) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-27 | Ivermectin (IVM) | BSA-Ivermectin (IVM); OVA-Ivermectin (IVM) | Anti-Ivermectin (IVM) mouse monoclonal antibody; Anti-Ivermectin (IVM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 3-4 | |
| GMP-SMT-28 | Tilmicosin(TIM) | BSA-Tilmicosin(TIM); OVA-Tilmicosin(TIM) | Anti-Tilmicosin(TIM) mouse monoclonal antibody; Anti-Tilmicosin(TIM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.60 | |
| GMP-SMT-29 | Tiamulin | BSA-Tiamulin; OVA-Tiamulin | Anti-Tiamulin mouse monoclonal antibody; Anti-Tiamulin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-30 | Acetylisovaleryl tylosin tartrate | BSA-Acetylisovaleryl tylosin tartrate; OVA-Acetylisovaleryl tylosin tartrate | Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody; Anti-Acetylisovaleryl tylosin tartrate human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 10.00 | |
| GMP-SMT-31 | Kitasamycin | BSA-Kitasamycin; OVA-Kitasamycin | Anti-Kitasamycin mouse monoclonal antibody; Anti-Kitasamycin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 20.00 | |
| GMP-SMT-32 | AlbendazoleI(ABZ) | BSA-AlbendazoleI(ABZ); OVA-AlbendazoleI(ABZ) | Anti-AlbendazoleI(ABZ) mouse monoclonal antibody; Anti-AlbendazoleI(ABZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 9-10 | |
| GMP-SMT-35 | Natamycin(NTM) | BSA-Natamycin(NTM); OVA-Natamycin(NTM) | Anti-Natamycin(NTM) mouse monoclonal antibody; Anti-Natamycin(NTM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-36 | Salinomycin(SLM) | BSA-Salinomycin(SLM); OVA-Salinomycin(SLM) | Anti-Salinomycin(SLM) mouse monoclonal antibody; Anti-Salinomycin(SLM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-37 | Monensi(MON) | BSA-Monensi(MON); OVA-Monensi(MON) | Anti-Monensi(MON) mouse monoclonal antibody; Anti-Monensi(MON) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-38 | Vancomycin(VM) | BSA-Vancomycin(VM); OVA-Vancomycin(VM) | Anti-Vancomycin(VM) mouse monoclonal antibody; Anti-Vancomycin(VM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.8-1 | |
| GMP-SMT-39 | Albendazole metabolite(ABZ) | BSA-Albendazole metabolite(ABZ); OVA-Albendazole metabolite(ABZ) | Anti-Albendazole metabolite(ABZ) mouse monoclonal antibody; Anti-Albendazole metabolite(ABZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-40 | Maduramicin | BSA-Maduramicin; OVA-Maduramicin | Anti-Maduramicin mouse monoclonal antibody; Anti-Maduramicin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-41 | Diclazuril | BSA-Diclazuril; OVA-Diclazuril | Anti-Diclazuril mouse monoclonal antibody; Anti-Diclazuril human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-1.5 | |
| GMP-SMT-42 | Toltrazuril (Methyl Triazine) | BSA-Toltrazuril (Methyl Triazine); OVA-Toltrazuril (Methyl Triazine) | Anti-Toltrazuril (Methyl Triazine) mouse monoclonal antibody; Anti-Toltrazuril (Methyl Triazine) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-43 | Levamisole | BSA-Levamisole; OVA-Levamisole | Anti-Levamisole mouse monoclonal antibody; Anti-Levamisole human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1.00 | |
| GMP-SMT-44 | Mebendazole | BSA-Mebendazole; OVA-Mebendazole | Anti-Mebendazole mouse monoclonal antibody; Anti-Mebendazole human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-45 | Triclabendazole | BSA-Triclabendazole; OVA-Triclabendazole | Anti-Triclabendazole mouse monoclonal antibody; Anti-Triclabendazole human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 5.00 | |
| GMP-SMT-47 | Amprolium | BSA-Amprolium; OVA-Amprolium | Anti-Amprolium mouse monoclonal antibody; Anti-Amprolium human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 30.00 | |
| GMP-SMT-48 | tetracycline | BSA-tetracycline; OVA-tetracycline | Anti-tetracycline mouse monoclonal antibody; Anti-tetracycline human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-49 | Oxytetracycline(OTCs) | BSA-Oxytetracycline(OTCs); OVA-Oxytetracycline(OTCs) | Anti-Oxytetracycline(OTCs) mouse monoclonal antibody; Anti-Oxytetracycline(OTCs) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-50 | Chlortetracycline | BSA-Chlortetracycline; OVA-Chlortetracycline | Anti-Chlortetracycline mouse monoclonal antibody; Anti-Chlortetracycline human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-51 | Doxycycline | BSA-Doxycycline; OVA-Doxycycline | Anti-Doxycycline mouse monoclonal antibody; Anti-Doxycycline human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-52 | Tetracyclines | BSA-Tetracyclines; OVA-Tetracyclines | Anti-Tetracyclines mouse monoclonal antibody; Anti-Tetracyclines human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-53 | Norfloxacin | BSA-Norfloxacin; OVA-Norfloxacin | Anti-Norfloxacin mouse monoclonal antibody; Anti-Norfloxacin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-55 | Sarafloxacin(SAR) | BSA-Sarafloxacin(SAR); OVA-Sarafloxacin(SAR) | Anti-Sarafloxacin(SAR) mouse monoclonal antibody; Anti-Sarafloxacin(SAR) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-56 | Ofloxacin(OFX) | BSA-Ofloxacin(OFX); OVA-Ofloxacin(OFX) | Anti-Ofloxacin(OFX) mouse monoclonal antibody; Anti-Ofloxacin(OFX) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.5-1 | |
| GMP-SMT-59 | Danofloxacin | BSA-Danofloxacin; OVA-Danofloxacin | Anti-Danofloxacin mouse monoclonal antibody; Anti-Danofloxacin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-60 | Difloxacin | BSA-Difloxacin; OVA-Difloxacin | Anti-Difloxacin mouse monoclonal antibody; Anti-Difloxacin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.5 | |
| GMP-SMT-61 | Quinolones | BSA-Quinolones; OVA-Quinolones | Anti-Quinolones mouse monoclonal antibody; Anti-Quinolones human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-62 | Ampicillin (Ampicillin, Amoxicillin,AMP) | BSA-Ampicillin (Ampicillin, Amoxicillin,AMP); OVA-Ampicillin (Ampicillin, Amoxicillin,AMP) | Anti-Ampicillin (Ampicillin, Amoxicillin,AMP) mouse monoclonal antibody; Anti-Ampicillin (Ampicillin, Amoxicillin,AMP) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.1-0.2 | |
| GMP-SMT-63 | Penicillin G | BSA-Penicillin G; OVA-Penicillin G | Anti-Penicillin G mouse monoclonal antibody; Anti-Penicillin G human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.1-0.2 | |
| GMP-SMT-64 | Ceftiofur(CEF) | BSA-Ceftiofur(CEF); OVA-Ceftiofur(CEF) | Anti-Ceftiofur(CEF) mouse monoclonal antibody; Anti-Ceftiofur(CEF) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-65 | Cefquinome(CEQ) | BSA-Cefquinome(CEQ); OVA-Cefquinome(CEQ) | Anti-Cefquinome(CEQ) mouse monoclonal antibody; Anti-Cefquinome(CEQ) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-66 | Cephalosporin(CEP) | BSA-Cephalosporin(CEP); OVA-Cephalosporin(CEP) | Anti-Cephalosporin(CEP) mouse monoclonal antibody; Anti-Cephalosporin(CEP) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-67 | Cephalexin(CEX) | BSA-Cephalexin(CEX); OVA-Cephalexin(CEX) | Anti-Cephalexin(CEX) mouse monoclonal antibody; Anti-Cephalexin(CEX) human monoclonal antibody; Recombinant beta-lactams sensor protein | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.4-0.5 | |
| GMP-SMT-68 | Hygromycin B(HMB) | BSA-Hygromycin B(HMB); OVA-Hygromycin B(HMB) | Anti-Hygromycin B(HMB) mouse monoclonal antibody; Anti-Hygromycin B(HMB) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-69 | Bacitracin(BCT) | BSA-Bacitracin(BCT); OVA-Bacitracin(BCT) | Anti-Bacitracin(BCT) mouse monoclonal antibody; Anti-Bacitracin(BCT) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-70 | Polymyxin B(PMB) | BSA-Polymyxin B(PMB); OVA-Polymyxin B(PMB) | Anti-Polymyxin B(PMB) mouse monoclonal antibody; Anti-Polymyxin B(PMB) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 10-20 | |
| GMP-SMT-72 | metoclopramide | BSA-metoclopramide; OVA-metoclopramide | Anti-metoclopramide mouse monoclonal antibody; Anti-metoclopramide human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.25 | |
| GMP-SMT-73 | Trimethoprim(TMP) | BSA-Trimethoprim(TMP); OVA-Trimethoprim(TMP) | Anti-Trimethoprim(TMP) mouse monoclonal antibody; Anti-Trimethoprim(TMP) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.20 | |
| GMP-SMT-74 | Polymyxin E(PME) | BSA-Polymyxin E(PME); OVA-Polymyxin E(PME) | Anti-Polymyxin E(PME) mouse monoclonal antibody; Anti-Polymyxin E(PME) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-75 | Cloxacillin | BSA-Cloxacillin; OVA-Cloxacillin | Anti-Cloxacillin mouse monoclonal antibody; Anti-Cloxacillin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 15.00 | |
| GMP-SMT-76 | Oxacillin | BSA-Oxacillin; OVA-Oxacillin | Anti-Oxacillin mouse monoclonal antibody; Anti-Oxacillin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 20.00 | |
| GMP-SMT-77 | Nitrofurazone metabolite (CPSEM) | BSA-Nitrofurazone metabolite (CPSEM); OVA-Nitrofurazone metabolite (CPSEM) | Anti-Nitrofurazone metabolite (CPSEM) mouse monoclonal antibody; Anti-Nitrofurazone metabolite (CPSEM) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.20 | |
| GMP-SMT-79 | Furazolidone metabolite (CPAOZ) | BSA-Furazolidone metabolite (CPAOZ); OVA-Furazolidone metabolite (CPAOZ) | Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody; Anti-Furazolidone metabolite (CPAOZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.50 | |
| GMP-SMT-80 | Furaltadone metabolite (CPAMOZ) | BSA-Furaltadone metabolite (CPAMOZ); OVA-Furaltadone metabolite (CPAMOZ) | Anti-Furaltadone metabolite (CPAMOZ) mouse monoclonal antibody; Anti-Furaltadone metabolite (CPAMOZ) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.30 | |
| GMP-SMT-85 | Benzoic Acid(BZA) | BSA-Benzoic Acid(BZA); OVA-Benzoic Acid(BZA) | Anti-Benzoic Acid(BZA) mouse monoclonal antibody; Anti-Benzoic Acid(BZA) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
| GMP-SMT-101 | Nitenpyram(NIT) | BSA-Nitenpyram(NIT); OVA-Nitenpyram(NIT) | Anti-Nitenpyram(NIT) mouse monoclonal antibody; Anti-Nitenpyram(NIT) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 2-3 | |
| GMP-SMT-111 | Arermectin | BSA-Arermectin; OVA-Arermectin | Anti-Arermectin mouse monoclonal antibody; Anti-Arermectin human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.3 | |
| GMP-SMT-132 | Ractopamine(RCT) | BSA-Ractopamine(RCT); OVA-Ractopamine(RCT) | Anti-Ractopamine(RCT) mouse monoclonal antibody; Anti-Ractopamine(RCT) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.10 | |
| GMP-SMT-134 | Salbutamol(SAL) | BSA-Salbutamol(SAL); OVA-Salbutamol(SAL) | Anti-Salbutamol(SAL) mouse monoclonal antibody; Anti-Salbutamol(SAL) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.2-0.25 | |
| GMP-SMT-137 | Clorprenaline(CLP) | BSA-Clorprenaline(CLP); OVA-Clorprenaline(CLP) | Anti-Clorprenaline(CLP) mouse monoclonal antibody; Anti-Clorprenaline(CLP) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 4-5 | |
| GMP-SMT-138 | CIMATEROL | BSA-CIMATEROL; OVA-CIMATEROL | Anti-CIMATEROL mouse monoclonal antibody; Anti-CIMATEROL human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.3-0.4 | |
| GMP-SMT-142 | Olaquindox(OLA) | BSA-Olaquindox(OLA); OVA-Olaquindox(OLA) | Anti-Olaquindox(OLA) mouse monoclonal antibody; Anti-Olaquindox(OLA) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 0.8-1 | |
| GMP-SMT-143 | Olaquindox metabolite(MQCA) | BSA-Olaquindox metabolite(MQCA); OVA-Olaquindox metabolite(MQCA) | Anti-Olaquindox metabolite(MQCA) mouse monoclonal antibody; Anti-Olaquindox metabolite(MQCA) human monoclonal antibody | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;Lateral flow immunoassay (LFIA); | 1-2 | |
Q&A
Q1: What are anti-small molecule antibodies and how do they impact veterinary healthcare?
A1: Anti-small molecule antibodies are specialized proteins engineered to bind with high specificity to small molecules, such as drug residues in veterinary medicine. They play a crucial role in veterinary healthcare by enabling precise detection of drug residues in animal products, ensuring the safety and compliance of these products with health standards.
Q2: How do small molecule competitive antigens aid in the treatment of drug residues?
A2: Small molecule competitive antigens act by mimicking the structure of drug residues, serving as decoys that bind to antibodies or receptors in place of the actual residues. This innovative approach helps mitigate the adverse effects of drug residues in animals, contributing to safer veterinary practices and healthier animal-derived products.
Q3: What types of veterinary drug residues are commonly monitored?
A3: Commonly monitored veterinary drug residues include antibiotics (e.g., tetracyclines, penicillins), hormones and growth promoters (e.g., trenbolone, zeranol), and antiparasitics (e.g., ivermectin). Monitoring these residues is essential for preventing antimicrobial resistance, ensuring food safety, and protecting consumer health.
Q4: What diagnostic methods are used to detect veterinary drug residues?
A4: Diagnostic methods for detecting veterinary drug residues include Enzyme-Linked Immunosorbent Assay (ELISA), Lateral Flow Immunoassay (LFIA), Colloidal Gold Immunochromatographic Assay, Chemiluminescent Immunoassay (CLIA), and Point-of-Care Testing (POCT). These methods offer sensitivity and specificity in detecting residues in animal tissues, milk, and eggs.
Q5: Why is the detection of veterinary drug residues important for public health?
A5: Detecting veterinary drug residues is crucial for public health as it helps prevent the entry of harmful residues into the food chain, reduces the risk of antimicrobial resistance, and ensures the safety of animal-derived products. Accurate detection and management of these residues are key to maintaining consumer confidence in food safety and protecting animal and human health.
Facebook
LinkedIn
Twitter
